Theodore Kopp, MD
Pain Medicine · Mobile, ALNPI 1437348711
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 442 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 33 manufacturers reported payments, led by Salix Pharmaceuticals, A Division Of Bausch Health US, LLC at 35.5% of the total. Reporting peaked in 2024 at $1,097 and has fallen 65.0% since, to $384 in 2025.
Across 442 payments — averaging $12.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- Amgen$472
- Collegium Pharmaceutical, Inc.$459
- Valinor Pharma, LLC$389
- Forte Bio-pharma LLC$368
- Arbor Pharmaceuticals, Inc.$281
- plus $2K from 27 others
What the payments were for
- Food & beverage$5,647100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 185 | $2,005 |
| Amgen | 36 | $472 |
| Collegium Pharmaceutical, Inc. | 24 | $459 |
| Valinor Pharma, LLC | 28 | $389 |
| Forte Bio-pharma LLC | 37 | $368 |
| Arbor Pharmaceuticals, Inc. | 18 | $281 |
| Medtronic(2 entities) | 22 | $256 |
| Daiichi Sankyo Inc. | 16 | $148 |
| Scilex Pharmaceuticals Inc. | 8 | $129 |
| Almatica Pharma LLC | 5 | $106 |
| Pacira Therapeutics, Inc. | 5 | $95 |
| Azurity Pharmaceuticals, Inc. | 6 | $94 |
| Biodelivery Sciences International, Inc. | 6 | $93 |
| AstraZeneca | 5 | $69 |
| Virtus Pharmaceuticals LLC | 3 | $68 |
| Redhill Biopharma Inc. | 4 | $60 |
| Boston Scientific | 4 | $60 |
| Hikma Pharmaceuticals USA | 4 | $59 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $55 |
| Vertex | 2 | $48 |
| Zyla Life Sciences, Inc. | 2 | $43 |
| Pfizer | 3 | $42 |
| Shionogi Inc | 2 | $35 |
| Kaleo, Inc. | 2 | $33 |
| Biotronik NRO, Inc. | 1 | $33 |
| Currax Pharmaceuticals LLC | 2 | $31 |
| Tonix Medicines, Inc. | 1 | $23 |
| Idorsia Pharmaceuticals US Inc | 1 | $20 |
| MDD US Operations, LLC | 1 | $20 |
| IBSA Pharma Inc. | 1 | $15 |
| Nevro Corp. | 1 | $14 |
| Novo Nordisk | 1 | $12 |
| Medline Industries LP | 1 | $11 |
How this compares
$5,647 in reported general payments places this provider in the 75th percentile of 77 pain medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RelistorMethylnaltrexone Bromide | 151 | $438,756 |
| BelbucaBuprenorphine Hcl | 658 | $428,768 |
| MovantikNaloxegol Oxalate | 162 | $136,523 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 5,817 | $136,149 |
| Buprenorphine | 621 | $128,037 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 2,780 | $118,407 |
| Xtampza ErOxycodone Myristate | 172 | $88,114 |
| LinzessLinaclotide | 106 | $72,639 |
| ProlateOxycodone Hcl/Acetaminophen | 20 | $50,032 |
| Gabapentin | 2,448 | $37,868 |
| Nucynta ErTapentadol Hcl | 51 | $36,114 |
| Diclofenac Sodium | 810 | $35,726 |
| Pregabalin | 1,095 | $34,404 |
| NucyntaTapentadol Hcl | 25 | $23,568 |
| Lidocaine | 212 | $21,764 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er, Nucynta Er, Nucynta | $459 | $576,564906 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $2,005 | $438,756151 claims |
| Hikma Pharmaceuticals USABuprenorphine, Buprenorphine-Naloxone, Kloxxado, Morphine Sulfate | $59 | $137,414740 claims |
| Redhill Biopharma Inc.Movantik | $60 | $136,523162 claims |
| Forte Bio-pharma LLCProlate | $368 | $50,03220 claims |
| Arbor Pharmaceuticals, Inc.Horizant | $281 | $10,53611 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $129 | $5,28715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 77 pain medicine providers in Alabama.
Other pain medicine in Mobile
- Grant StoneMobile$11K
- Tao ChenMobile$3K
- Anthony MaggioMobile$3K
- Ralph IrvinMobile$2K
- Cassie BurnsMobile$1K
- Christopher PaulBirmingham$64K
- Michael CosgroveHuntsville$25K
- Ron PitkanenMountain Brk$16K
- Elliott PenningtonDaphne$15K
- James ThackerHuntsville$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.